Subscribe to RSS

DOI: 10.1055/a-2690-1674
Racial Differences in Bleeding Risks among Patients with Atrial Fibrillation: An Ecological Epidemiological Study Comparing Korea and UK Population
Funding This research was supported by a grant of Patient-Centered Clinical Research Coordinating Center (PACEN) funded by the Ministry of Health & Welfare, Republic of Korea (RS-2024-00397290).

Abstract
Background
Racial differences in the propensity to bleeding may be evident, with a higher risk of bleeding in Asian populations. This study aimed to assess racial differences in bleeding risk among patients with atrial fibrillation (AF) using an ecological epidemiological approach.
Methods
We included patients with AF from the Korean National Health Insurance Service-Health Screening and UK Biobank who underwent health check-ups between 2006 and 2010. The analysis involved 1928 East Asians (62.1% male, median age 60.0 years) and 5917 White Europeans (71.4% male, median age 64.0 years) were analyzed. Primary outcome was composed of intracranial hemorrhage and bleeding from the gastrointestinal, respiratory, and genitourinary systems.
Results
During follow-up, the primary outcome occurred in 126 East Asians and 587 White Europeans. East Asians had a 42% lower 5-year incidence rate compared with White Europeans (weighted incidence rate 1.31 vs. 2.24 per 100 person-years; incidence rate ratio 0.58, 95% confidence interval: 0.41–0.83). Contrary to the primary outcome, the incidence of intracranial hemorrhage tended to be higher among East Asians (weighted incidence rate 0.34 vs. 0.14 per 100 person-years; incidence rate ratio 2.36, 95% confidence interval: 0.88–6.37). These results persisted even in patients naïve to antithrombotic drugs. East Asians who were already taking antithrombotic drugs at baseline showed no significant difference in the incidence of the primary outcome compared with White Europeans.
Conclusion
This ecological study highlights racial differences in the incidence of bleeding influenced by anatomical site and antithrombotic drug use and underscores the necessity for race-based tailored approaches.
Keywords
racial difference - atrial fibrillation - intracranial hemorrhage - gastrointestinal bleedingData Availability Statement
Data from K-NHIS-HealS are available on the Web site (http://nhiss.nhis.or.kr). Data from UK Biobank are available upon application.
Authors' Contribution
D.S.K. and P.S.Y. contributed equally to this work. G.Y.H.L. and B.J. contributed to the conception and design of the work and critical revision of the manuscript. D.S.K. contributed to the conception and design of the work, analysis and interpretation of data, and drafting of the manuscript. P.S.Y., D.K., and E.J. contributed to data extraction and analysis. H.T.Y., T.H.K., J.H.S., and H.N.P. contributed to the conception and design of the work and revision of the manuscript. All authors approved the final version to be published. Also, they are responsible for ensuring that questions relating to accuracy or integrity of all parts of the work are properly investigated and resolved. The corresponding author certifies that all listed authors meet authorship criteria.
* These authors contributed equally to this work.
** These authors are joint senior authors.
The review process for this paper was fully handled by Christian Weber, Editor in Chief.
Publication History
Received: 06 May 2025
Accepted: 25 August 2025
Accepted Manuscript online:
26 August 2025
Article published online:
09 September 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1 Chao TF, Joung B, Takahashi Y. et al. 2021 focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: executive summary. Thromb Haemost 2022; 122 (01) 20-47
- 2 Wang Y, Guo Y, Qin M. et al. Chinese expert consensus guidelines on the diagnosis and treatment of Atrial Fibrillation in the Elderly. Executive Summary. Thromb Haemost 2024; 2024
- 3 Ivany E, Lotto RR, Lip GYH, Lane DA. Managing uncertainty: physicians' decision making for stroke prevention for patients with atrial fibrillation and intracerebral hemorrhage. Thromb Haemost 2022; 122 (09) 1603-1611
- 4 Gorog DA, Gue YX, Chao TF. et al. Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper. Thromb Haemost 2022; 122 (10) 1625-1652
- 5 Kang DS, Yang PS, Kim D. et al. Racial differences in ischemic and hemorrhagic stroke: an ecological epidemiological study. Thromb Haemost 2024; 124 (09) 883-892
- 6 Kim HK, Tantry US, Smith Jr SC. et al. The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost 2021; 121 (04) 422-432
- 7 Norby FL, Benjamin EJ, Alonso A, Chugh SS. Racial and ethnic considerations in patients with atrial fibrillation: JACC Focus Seminar 5/9. J Am Coll Cardiol 2021; 78 (25) 2563-2572
- 8 Kang DS, Yang PS, Kim D. et al. Racial differences in bleeding risk: an ecological epidemiological study comparing Korea and United Kingdom subjects. Thromb Haemost 2024; 124 (09) 842-851
- 9 Lee SS, Ae Kong K, Kim D. et al. Clinical implication of an impaired fasting glucose and prehypertension related to new onset atrial fibrillation in a healthy Asian population without underlying disease: a nationwide cohort study in Korea. Eur Heart J 2017; 38 (34) 2599-2607
- 10 Sudlow C, Gallacher J, Allen N. et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 2015; 12 (03) e1001779
- 11 Khurshid S, Weng LC, Al-Alusi MA. et al. Accelerometer-derived physical activity and risk of atrial fibrillation. Eur Heart J 2021; 42 (25) 2472-2483
- 12 Chao TF, Liu CJ, Tuan TC. et al. Lifetime risks, projected numbers, and adverse outcomes in Asian patients with atrial fibrillation: a report from the Taiwan nationwide AF cohort study. Chest 2018; 153 (02) 453-466
- 13 Kim BY, Kang SM, Kang JH. et al; Committee of Clinical Practice Guidelines, Korean Society for the Study of Obesity (KSSO). 2020 Korean Society for the study of obesity guidelines for the management of obesity in Korea. J Obes Metab Syndr 2021; 30 (02) 81-92
- 14 Wharton S, Lau DCW, Vallis M. et al. Obesity in adults: a clinical practice guideline. CMAJ 2020; 192 (31) E875-E891
- 15 Feigin VL, Krishnamurthi RV, Parmar P. et al; GBD 2013 Writing Group, GBD 2013 Stroke Panel Experts Group. Update on the Global Burden of Ischemic and Hemorrhagic Stroke in 1990-2013: the GBD 2013 Study. Neuroepidemiology 2015; 45 (03) 161-176
- 16 Yamashita T, Koretsune Y, Yang Y. et al. Edoxaban vs. Warfarin in East Asian Patients With Atrial Fibrillation - An ENGAGE AF-TIMI 48 Subanalysis. Circ J 2016; 80 (04) 860-869
- 17 Goto S, Zhu J, Liu L. et al; ARISTOTLE Investigators. Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J 2014; 168 (03) 303-309
- 18 Kim JS, Kim YJ, Ahn SH, Kim BJ. Location of cerebral atherosclerosis: why is there a difference between East and West?. Int J Stroke 2018; 13 (01) 35-46
- 19 Lovelock CE, Cordonnier C, Naka H. et al. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies. Stroke 2010; 41 (06) 1222-1228
- 20 Kim T, Kwon OK, Bang JS. et al. Epidemiology of ruptured brain arteriovenous malformation: a National Cohort Study in Korea. J Neurosurg 2018; 130 (06) 1965-1970
- 21 Querfurth H, Marczak I, Rahimian N, Jijakli A, Green-LaRoche D. Spontaneous intracranial hemorrhages in a community of Asian Americans: case series and literature review. Cureus 2024; 16 (01) e52128
- 22 Cha JM, Moon JS, Chung IK. et al. National endoscopy quality improvement program remains suboptimal in Korea. Gut Liver 2016; 10 (05) 699-705
- 23 Wang FW, Chuang HY, Tu MS. et al. Prevalence and risk factors of asymptomatic colorectal diverticulosis in Taiwan. BMC Gastroenterol 2015; 15: 40
- 24 Cho YK. How to improve the quality of screening endoscopy in Korea: national endoscopy quality improvement program. Clin Endosc 2016; 49 (04) 312-317
- 25 Romiti GF, Pastori D, Rivera-Caravaca JM. et al. Adherence to the ‘Atrial Fibrillation Better Care’ pathway in patients with atrial fibrillation: impact on clinical outcomes-a systematic review and meta-analysis of 285,000 patients. Thromb Haemost 2022; 122 (03) 406-414
- 26 van Walraven C, Hart RG, Singer DE. et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002; 288 (19) 2441-2448
- 27 Mant J, Hobbs FD, Fletcher K. et al; BAFTA investigators, Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370 (9586) 493-503
- 28 Chao TF, Chen SA, Ruff CT. et al. Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. Eur Heart J 2019; 40 (19) 1518-1527
- 29 Takahashi H, Wilkinson GR, Caraco Y. et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther 2003; 73 (03) 253-263
- 30 Takahashi H, Wilkinson GR, Nutescu EA. et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006; 16 (02) 101-110
- 31 Chan HT, So LT, Li SW, Siu CW, Lau CP, Tse HF. Effect of herbal consumption on time in therapeutic range of warfarin therapy in patients with atrial fibrillation. J Cardiovasc Pharmacol 2011; 58 (01) 87-90
- 32 Gage BF, Eby C, Johnson JA. et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008; 84 (03) 326-331
- 33 JCS Joint Working Group. JCS 2013. Circ J 2014; 78 (08) 1997-2021
- 34 Chiang CE, Wang KL, Lin SJ. Asian strategy for stroke prevention in atrial fibrillation. Europace 2015; 17 (Suppl. 02) ii31-ii39
- 35 Fry A, Littlejohns TJ, Sudlow C. et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. Am J Epidemiol 2017; 186 (09) 1026-1034